echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > IBD: Levels of fatty antibiotics in children diagnosed with Crohn's disease can predict the therapeutic effects of biologics.

    IBD: Levels of fatty antibiotics in children diagnosed with Crohn's disease can predict the therapeutic effects of biologics.

    • Last Update: 2020-10-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Although routine assessments of disease activity in Crohn's disease (CD) can be made through serum markers, abdominal CT imaging and endoscopy, markers with better prognostic value are needed to predict the prognosis of the disease.
    It has long been thought that fatty visceral adipose tissue (VAT) associated with intestinal inflammation is a major feature of CD, and studies have reported a relatively high proportion of VATs in children with CD, whether obese or not, and associated with adverse outcomes.
    a wide range of metabolic, biochemical, immune, inflammatory, and microbial level changes in adipose tissue, including secretion of bioactive molecules called fat factors.
    , especially the active fat factor immune, affects a variety of inflammatory pathways.
    , this study aims to explore whether serum fat factor levels and VAT can be used as predictors of disease prognosis and treatment effectiveness in newly diagnosed CHILDREN with CD.
    researchers recruited CD patients between the ages of 6 and 20 and obtained their clinical and anthotic data.
    the levels of fat factors were measured at 0, 6 and 12 months, respectively, after CD diagnosis and in the baseline (CP) of the control group.
    the levels of visceral fat (VAT) with magnetic resonance imaging or computer lithography within 3 months of diagnosis.
    the study included 104 patients with routine colonoscopy: 36 diagnosed with CD and 68 with control (CP).
    levels of lipid antibiotics and lysolysase primary activator inhibitors (PAI)-1 were significantly higher than CP in patients diagnosed with CD.
    VAT is similar between CD and CP.
    CD patients who gradually upgraded to biologics had significantly higher baseline resistance levels at diagnosis than those who did not use biotherapy (29.8 ng / mL VS 13.8 ng / mL; P - 0.004).
    levels ≥29.8ng / mL at the time of diagnosis are predicted to be 95% specific to biotherapy in the first year after diagnosis (sensitivity s 53%; area under curve s 0.82; P s 0.015).
    levels at the time of diagnosis in patients with CD in children can predict the possibility of gradual escalation to biotherapy after 12 months, independent of VAT.
    levels of antibiotics and PAI-1 in CD patients treated with biologics increased significantly compared to patients who did not use biologics.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.